Browsing by Author "Balmaceda C."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Medication review with follow-up for cardiovascular outcomes: A trial based cost-utility analysis
    (Academic Press, 2021) Ahumada-Canale A.; Martinez-Mardones F.; Garcia-Cardenas V.; Ahumada-Canale A.; Vargas C.; Balmaceda C.; Plaza-Plaza J.C.; Benrimoj S.
    © 2021 Future Medicine Ltd.. All rights reserved.Aim: To assess the trial-based cost-effectiveness of medication review with follow-up compared with usual care in primary care. Materials methods: A cluster randomized controlled trial included patients if they were independent older adults, receiving five or more prescriptions, with moderate or high cardiovascular risk. Costs were estimated from the public healthcare sector perspective, and health benefits were measured as quality-Adjusted life years. Both of which were used to calculate the incremental cost-effectiveness ratio. Results: Twelve centers completed the study, six (146 patients) in the intervention group and six (145 patients) in the control group. The base-case analysis showed an incremental cost-effectiveness ratio of US (2019) 434.4/quality-Adjusted life year (95% CI 64.20-996.03). Conclusion: The intervention was cost-effective in the public primary care setting.
  • No Thumbnail Available
    Item
    Tacitus and the men of merit in the reign of TiberiusTácito y los hombres de mérito bajo el reinado de Tiberio
    (Springer International Publishing, 2023) Balmaceda C.
    © 2023 Departamento de Literatura Española-Universidad de Sevilla. All rights reserved.This work analizes the characters that Tacitus highlights as worthy of merit during the new political system of the Principate and that receive praise or approval by the historian in the first hexad of his Annals. The paper also examines the elements that constitute merit during Tiberius’ reign and that receive some kind of political compensation by the emperor.
  • No Thumbnail Available
    Item
    The expected cost of cancer in ChileEl costo esperado de cáncer en Chile
    (Springer, 2022) Espinoza M.A.; Armijo N.; Abbott T.; Jimenez J.; Balmaceda C.; CEDEUS (Chile)
    © 2022 Sociedad Medica de Santiago. All rights reserved.Background: Cancer is a public health priority in Chile. Aim: To estimate the expected annual cost of cancer in Chile, due to direct costs of health services, working allowances and indirect costs for productivity losses. Material and Methods: We undertook an ascendent costing methodology to calculate direct costs. We built diagnostic, treatment and follow-up cost baskets for each cancer type. Further, we estimated the expenditure due to sick leave subsidies. Both estimates were performed either for the public or private sector. Costs related to productivity loss were estimated using the human capital approach, incorporating disease related absenteeism premature deaths. The time frame for all estimates was one year. Results: The annual expected costs attributed to cancer was $1,557 billion of Chilean pesos. The health services expected annual costs were $1,436 billion, 67% of which are spent on five cancer groups (digestive, hematologic, respiratory, breast and urinary tract). The expected costs of sick leave subsidies and productivity loss were $48 and $71 billion, respectively. Conclusions: Cancer generates costs to the health system, which obliges health planners to allocate a significant proportion of the health budget to this disease. The expected costs estimated in this study are equivalent to 8.9% of all health expenditures and 0.69% of the Gross Domestic Product. This study provides an updated reference for future research, such as those aimed at evaluating the current health policies in cancer.